Add Company
Join Now

MimiVax Revenue and Competitors

License our Company Data API

Buffalo, NY USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • MimiVax's estimated annual revenue is currently $620k per year.(i)
  • MimiVax's estimated revenue per employee is $155,000

Employee Data

  • MimiVax has 4 Employees.(i)
  • MimiVax grew their employee count by 0% last year.

MimiVax's People

NameTitleEmail/Phone
1
VP Clinical OperationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M40%N/AN/A
#2
$3.7M2441%$44MN/A
#3
$6.2M40-7%N/AN/A
#4
$42M271-1%N/AN/A
#5
$12.7M820%$10MN/A
#6
$2.5M160%N/AN/A
#7
$7.5M450%$51.6MN/A
#8
$0.2M1-50%N/AN/A
#9
$4.3M26-16%$3.3MN/A
#10
$3.7M244%N/AN/A
Add Company

What Is MimiVax?

Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates\n\nMimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer. \n\nSurVaxM, our lead immunotherapeutic vaccine, has completed a Phase 2a clinical trial in adults with newly diagnosed glioblastoma. \n\nAdditional indications are being evaluated through: \n- Phase 1 clinical trials in multiple myeloma combination with REVLIMID® (lenalidomide) \n- Phase 1 in Neuro-Endocrine Tumors (NET)\n- Pilot Study in Pediatric High Grade Glioma, recurrent/relapsed Medulloblastoma and DIPG

keywords:N/A

N/A

Total Funding

4

Number of Employees

$620k

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.6M40%N/A
#2
$0.3M4-33%N/A
#3
$0.3M40%N/A
#4
$0.3M4N/AN/A
#5
$0.4M433%N/A